Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Common Equity data on file, last reported at -$236.0 million in Q1 2026.

• On a quarterly basis, Common Equity fell 263.89% year-over-year to -$236.0 million in Q1 2026; TTM through Mar 2026 was -$236.0 million, a 263.89% decrease from a year earlier, with the FY2025 full-year figure at -$80.0 million, down 131.37% from the prior year.
• Common Equity for Q1 2026 stood at -$236.0 million, down from -$80.0 million in the prior quarter.
• Over the last five years, Common Equity for RARE reached as high as $796.4 million in Q1 2022 and fell as low as -$236.0 million in Q1 2026.
• Historically, Common Equity has averaged $242.0 million across 5 years, with a median of $220.5 million in 2023.
• Across the five-year window, Common Equity surged 993.61% in 2024 and slumped 263.89% in 2026, its largest moves.
• Year by year, Common Equity stood at $352.0 million in 2022, then declined by 21.88% to $275.0 million in 2023, then retreated by 7.27% to $255.0 million in 2024, then slumped by 131.37% to -$80.0 million in 2025, then tumbled by 195.0% to -$236.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$236.0 million in Q1 2026, -$80.0 million in Q4 2025, and $9.2 million in Q3 2025.